Business
GeneCentric Therapeutics Announces American Medical Association Has Granted a PLA Code for PurIST Pancreatic Cancer Test
PurISTSM is an RNA expression-based test licensed to Tempus AI to help inform and personalize treatment for patients with pancreatic cancer The PurIST
About this update from Tempus Ai, Inc.
[{"type":"text","content":"\nPurISTSM is an RNA expression-based test licensed to Tempus AI to help inform and personalize treatment for patients with pancreatic cancer\n\n\nThe PurIST proprietary laboratory analysis (PLA) code is the first common procedural terminology (CPT) code created for algorithm-based analysis of previously sequenced RNA data from a laboratory developed test (LDT)\n\n\n DURHAM, N.C.--(BUSINESS WIRE)--\nGeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today that the American Medical Association (AMA) has granted a PLA code for the PurISTSM pancreatic cancer test. PurIST is commercially available under a collaboration agreement with Tempus AI, Inc. (NASDAQ: TEM) and run on its xR platform. The PurIST PLA code is the first CPT code created to describe an algorithm-only analysis from previously sequenced, LDT, transcriptomic (RNA) data and represents a meaningful step toward reimbursement for AI-enabled algorithms.\n\n\n“Receipt of a PurIST-specific PLA test code further supports the significance of GeneCentric’s pipeline of next-generation AI-derived tests,” said Michael Milburn, PhD, President and CEO of GeneCentric Therapeutics. “This is a key step toward reimbursement and successful commercialization for PurIST, and we’re excited about the importance of this test in guiding first-line treatments for pancreatic cancer patients.”\n\n\nPancreatic cancer has one of the highest mortality rates among all major cancers, and there has been limited availability of validated diagnostic tests or biomarkers to guide first-line treatment selection. The PurIST test classifies the tumors of patients with unresectable stage III or stage IV pancreatic ductal adenocarcinoma (PDAC) as either a basal or classical subtype and can help guide first-line therapy.\n\n\nAbout the PurIST Test\n\n\nPurIST identifies the molecular subtype of patients with unresectable stage III or stage IV PDAC and classifies patients with PDAC into either a basal or classical subtype and may help inform first-line therapy management. Tempus and GeneCentric recently completed a new clinical validation study demonstrating that PurIST can be used to help predict overall survival of classical patients between standard-of-care first-line therapies, FOLFIRINOX and gemcitabine nab-paclitaxel. The PurIST test is avail...